peptide compounding FAQ

Document clinical justification beyond cost. Once Mounjaro and Zepbound return to consistent supply, the FDA's enforcement stance shifts—compounding is permitted only when FDA-approved alternatives don't meet the patient's clinical needs. Acceptable justifications include allergy to a branded formulation's excipients, need for a non-standard dose not commercially available, or documented adverse reaction to the branded product's delivery device. Cost alone won't satisfy state board or FDA scrutiny if a patient experiences adverse outcomes.

Switch to a 503B-registered facility with confirmed nominations before March 2026. Contact your current pharmacy and request written confirmation of their 503B status and proof that the peptides you prescribe are either nominated or appear on the FDA's approved bulk drug substances list. If they can't provide documentation, transition patients to a verified 503B supplier immediately—mid-treatment supply disruptions create adherence gaps that trigger weight regain and metabolic rebound.

Verify that your pharmacy holds active registration in every state where your patients reside. Federal 503B status authorises interstate distribution, but it doesn't override state-specific registration requirements. Florida, Texas, and California all require out-of-state pharmacies to register with their state boards before shipping compounded medications to residents. Prescribing to a patient in a state where your pharmacy isn't registered exposes both you and the pharmacy to enforcement action and creates liability if the patient experiences harm.

You have two legal pathways: direct importation under an FDA research exemption (requires IND or investigational use documentation), or custom synthesis through a cGMP-certified manufacturer that ships directly to your facility rather than through a compounding pharmacy. The first pathway is practical only for institutional research with existing FDA relationships. The second pathway works but is expensive. Minimum order quantities for custom synthesis typically start at 50–100 grams, and per-gram costs run $800–$3,500 depending on sequence complexity. For peptides like Dihexa or SLU PP 332 that require multi-step synthesis, lead times are 16–20 weeks.

Orders placed and shipped before the March 1, 2026 enforcement date are not retroactively non-compliant, but you cannot reorder through the same pathway. The 503A interstate shipping restriction applies prospectively. If your research protocol requires ongoing peptide supply, you need to establish a relationship with a 503B facility or transition to direct-import research-grade peptides that comply with your institutional IRB and procurement policies. Many research sites shifted to European or Canadian peptide suppliers in Q2 2026 because international shipments to registered research institutions are exempt from 503A/503B domestic compounding restrictions. Though import compliance (CBP declarations, FDA research use documentation) remains your responsibility.

Request documentation of their API supplier's cGMP certification and their own 503B registration. If they're a 503A pharmacy claiming they can still ship bulk research peptides interstate. They're either misinformed or non-compliant. The 90-day supply cap applies to all 503A interstate shipments as of March 1, 2026, and enforcement actions began May 1, 2026. If they're a 503B facility, verify their registration number through the FDA's Outsourcing Facilities list. It's publicly searchable. Unregistered facilities cannot legally claim 503B status, and misrepresentation carries criminal penalties under 21 USC 331(a).